Drug
Surufatinib clinical trials
Also written HMPL-012 and Sulfatinib.
- studies test it
- 80
- open now
- 39
- in phase 3
- 5
- first study started
- 2010
Keep track of what changes. Save the surufatinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
80 studies that test it; most in 2022 (17)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2020 | 5 |
| 2021 | 16 |
| 2022 | 17 |
| 2023 | 14 |
| 2024 | 10 |
| 2025 | 4 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 21
- Phase 2
- 64
- Phase 3
- 5
- Phase 4
- 1
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 61
Hutchison Medipharma Limited (15) · Sun Yat-sen University (11) · Fudan University (6) · Fujian Cancer Hospital (6) · Tianjin Medical University Cancer Institute and Hospital (4) · Hutchmed (3) · Second Affiliated Hospital, School of Medicine, Zhejiang University (3) · Wuhan Union Hospital, China (2)
Often tested with
Tested in the same studies.
Sintilimab (10) · Toripalimab (9) · Tislelizumab (5) · Gemcitabine (4) · Albumin-Bound Paclitaxel (4) · Paclitaxel (4) · Cisplatin (3) · Serplulimab (3)
Studies
Open first, then newest update. How each study uses surufatinib is read from its arms, and is right about nine times in ten.
Testing it · 80
- Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian CancerRecruitingPhase 2Bai-Rong XiaNCT05652283Written as Surufatinib
- A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.RecruitingPhase 1/2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT05747729Written as Surufatinib and Serplulimab
- Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic CancerRecruitingPhase 3Tianjin Medical University Cancer Institute and HospitalNCT07436741Written as surufatinib + gemcitabine + nab-paclitaxel
- Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLCRecruitingPhase 2Sun Yat-sen UniversityNCT07609121Written as Surufatinib
- Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic CancerNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07469956Written as Surufatinib
- Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung CancerRecruitingPhase 2Sun Yat-sen UniversityNCT06719700Written as Consolidation Therapy with Toripalimab and Surufatinib
- Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine NeoplasmsRecruitingPhase 4Shanghai Zhongshan HospitalNCT07272512Written as Surufatinib
- Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix CarcinomaRecruitingPhase 2Sun Yat-sen UniversityNCT05472948Written as Surufatinib
- Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging SystemNot yet recruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07279532Written as surufatinib
- Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine CarcinomaNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07156019Written as Sintilimab+Temozolomide+Surufatinib
- A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic CancerRecruitingPhase 2Fudan UniversityNCT05969171Written as Surufatinib, gemcitabine, nab-paclitaxel
- Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung CancerRecruitingPhase 2Sun Yat-sen UniversityNCT07086456Written as Surufatinib
- Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)RecruitingPhase 2Peking UniversityNCT05165407Written as Surufatinib
- Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic CancerRecruitingPhase 1/2Chinese PLA General HospitalNCT05218889Written as surufatinib + camrelizumab + nab-paclitaxel + S-1
- A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.Not yet recruitingPhase 2Fujian Cancer HospitalNCT06654947Written as Surufatinib+Toripalimab+GEMOX
- Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract CancerRecruitingPhase 2Dai, GuanghaiNCT06708858Written as Surufatinib
- Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract CarcinomaNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT06656559Written as Envafolimab and Surufatinib
- Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine DifferentiationNot yet recruitingPhase 2RenJi HospitalNCT06531291Written as Surufatinib
- Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic CancerRecruitingPhase 1/2Shanghai Zhongshan HospitalNCT05832892Written as surufatinib
- Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine DifferentiationNot yet recruitingPhase 2National Cancer Center, ChinaNCT06414915Written as Surufatinib
See all 80 studies that test surufatinib →
Given in every arm · 1 — surufatinib is usual care beside what is tested
As the comparator · 1 — what is tested is compared with surufatinib
Codes
What other systems call surufatinib · ClinicalTrials.gg INT001634
- MeSH (NLM) C000717729surufatinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) B2K5L1L8S9SURUFATINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q126122215surufatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C116066SurufatinibOne source FDA
- DrugBank DB15106One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000717729 | surufatinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | B2K5L1L8S9 | SURUFATINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q126122215 | surufatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C116066 | Surufatinib | One source FDA |
| DrugBank | DB15106 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.